Post-IPO Equity - CombiGene
Investment Firm
Overview
CombiGene provides patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.
Announced Date
Feb 21, 2024
Funding Type
Post Ipo Equity
Highlights
N/A
Location
N/A
Social
N/A
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 Orphazyme |
Round Details and Background
CombiGene raised an undisclosed amount on 2024-02-21 in Post-IPO Equity
CombiGene provides patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.
Company Funding History
2
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| May 23, 2018 | 1 | - | 3.9M | |
| Feb 21, 2024 | 1 | - | undefined |
Recent Activity
There is no recent news or activity for this profile.